Nevirapin Ratiopharm (Nevirapine)

Nevirapine is used in antiretroviral therapy targeting HIV‑1 replication.

• HIV‑1 infection: reduces viral load when combined with other antiretrovirals in treatment‑naïve patients.
• Treatment‑experienced HIV‑1 infection: provides an alternative NNRTI option for patients with prior regimen failure.
• Pediatric HIV‑1 infection (≥2 years): contributes to viral suppression as part of age‑appropriate combination therapy.

• Nevirapine binds to a hydrophobic pocket on the HIV‑1 reverse transcriptase enzyme at a site distinct from the nucleoside binding region. This non‑nucleoside attachment induces a conformational change that blocks the enzyme’s polymerase activity, preventing transcription of viral RNA into DNA and thereby halting viral replication within infected cells. The inhibition is reversible and does not require intracellular phosphorylation, allowing rapid onset of antiviral effect after oral administration.

Nevirapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Rash: mild to moderate skin eruptions.
• Nausea: transient gastrointestinal discomfort.
• Headache: mild to moderate intensity.
• Fatigue: general tiredness.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention.
• Hepatotoxicity: elevated liver enzymes or hepatitis, potentially leading to liver failure.
• Severe hypersensitivity: fever, eosinophilia, and systemic symptoms.
• Neutropenia: marked reduction in white blood cells increasing infection risk.

Before initiating therapy, clinicians should consider several safety measures.

• Liver function monitoring: assess baseline transaminases and repeat during therapy.
• Hepatitis B/C co‑infection: use with caution due to increased risk of hepatic injury.
• Pregnancy considerations: evaluate risk‑benefit, as safety data are limited.
• Drug resistance: avoid monotherapy to prevent emergence of resistant HIV strains.
• Concomitant CYP inducers: avoid strong inducers that may reduce nevirapine levels.
• Store at room temperature (below 25°C): keep in the original container, protect from moisture and light.

Nevirapine interacts with several medicines that can alter its effectiveness or safety.

Major Interactions (Avoid)

• Rifampicin: strong enzyme inducer that markedly lowers nevirapine plasma concentrations.
• St. John’s wort: herbal inducer that reduces drug exposure.
• Carbamazepine: CYP3A4 inducer leading to subtherapeutic levels.

Moderate Interactions (Monitor Closely)

• Protease inhibitors (e.g., lopinavir/ritonavir): may increase nevirapine levels and risk of toxicity.
• Azole antifungals (e.g., ketoconazole): can raise nevirapine concentrations.
• Hormonal contraceptives: nevirapine may reduce efficacy, requiring alternative contraception.